Literature DB >> 19397686

Mesangial medium with IgA1 from IgA nephropathy inhibits nephrin expression in mouse podocytes.

C Wang1, X Liu, Z Ye, J Zhang, H Tang, Z Chen, H Zhang, T Lou.   

Abstract

BACKGROUND: IgA nephropathy (IgAN) is characterized by mesangial deposition of polymeric IgA1, and podocyte injury plays an important role in glomerulosclerosis of the disease. Our previous study indicated that medium of mesangial cells co-incubated with aggregated IgA1 (aIgA1), isolated from IgAN patients, down-regulated nephrin expression. Yet the mechanism remains unclear.
MATERIALS AND METHODS: Podocytes were incubated with a medium of mesangial cells co-incubated with aIgA1, which was isolated from IgAN patients, and enalaprilat (10(-5) M), valsartan (10(-5) M) and anti-mouse tumour necrosis factor-alpha antibody (50 ng mL(-1)) separately. Nephrin expression in podocytes was measured by real-time polymerase chain reaction and Western blot analysis.
RESULTS: The level of angiotensinogen and angiotensin-converting enzyme mRNAs in podocytes, as well as angiotensin, was also increased by a medium of mesangial cells co-incubated with aIgA1 from IgAN patients (P<0.05). Enalaprilat or valsartan partly improved nephrin expression when compared with that by podocytes exposed to the mesangial medium (P<0.05), while the nephrin expression of podocytes with enalaprilat or valsartan was lower than that of podocytes exposed to medium of mesangial cells stimulated by aIgA1 from healthy control (P<0.05). However, anti-mouse tumour necrosis factor-alpha antibody did not show any improvement in nephrin expression.
CONCLUSION: Our findings implicate that local renin angiotensin system activation in podocytes is partly involved in down-regulation of nephrin by mesangial medium in IgA nephropathy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19397686     DOI: 10.1111/j.1365-2362.2009.02135.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  3 in total

1.  Urokinase-type plasminogen activator receptor in IgA nephropathy.

Authors:  Shin-Young Ahn; Ho Jun Chin
Journal:  Korean J Intern Med       Date:  2014-02-27       Impact factor: 2.884

2.  Immunosuppressive Treatment in Children With IgA Nephropathy and the Clinical Value of Podocytopathic Features.

Authors:  Alexandra Cambier; Marion Rabant; Michel Peuchmaur; Alexandre Hertig; Georges Deschenes; Cecile Couchoud; Anne Kolko; Remi Salomon; Julien Hogan; Thomas Robert
Journal:  Kidney Int Rep       Date:  2018-03-29

3.  SUMO1 Promotes Mesangial Cell Proliferation Through Inhibiting Autophagy in a Cell Model of IgA Nephropathy.

Authors:  Xia Tan; Yexin Liu; Di Liu; Xiaofang Tang; Ming Xia; Guochun Chen; Liyu He; Xuejing Zhu; Hong Liu
Journal:  Front Med (Lausanne)       Date:  2022-03-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.